ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week
This study has been terminated.
(The trial was terminated due to lack of compliance with GCP regulations.)
Sponsor:
Sanofi-Aventis
Collaborator:
Procter and Gamble
Information provided by:
Sanofi-Aventis
ClinicalTrials.gov Identifier:
NCT00544180
First received: October 15, 2007
Last updated: September 24, 2009
Last verified: September 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.
Condition | Intervention | Phase |
---|---|---|
Osteoporosis |
Drug: Risedronate |
Phase 4 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Record on Satisfaction of Patients With Actonel 35 mg Once a Week |
Resource links provided by NLM:
MedlinePlus related topics:
Osteoporosis
Drug Information available for:
Risedronate sodium
U.S. FDA Resources
Further study details as provided by Sanofi-Aventis:
Eligibility
Ages Eligible for Study: | 55 Years to 80 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria :
- Postmenopausal ambulatory women
- Established osteoporosis
Exclusion criteria:
- History of cancer: basal cell or squamous cell carcinoma-documented 6-month remission,
- Diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
More Information
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
No publications provided
Responsible Party: | Medical Affairs Study Director, sanofi-aventis |
ClinicalTrials.gov Identifier: | NCT00544180 History of Changes |
Other Study ID Numbers: | RISED_L_01686 |
Study First Received: | October 15, 2007 |
Last Updated: | September 24, 2009 |
Health Authority: | Israel: Ministry of Health |
Additional relevant MeSH terms:
Osteoporosis Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases Risedronic acid Bone Density Conservation Agents Physiological Effects of Drugs |
Pharmacologic Actions Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on October 17, 2012